Campona Airmaster™
(Salmeterol / Fluticasone)
Prescribing Information can be FOUND HERE
Asthma
Campona Airmaster™ is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:
patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or
patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist
Note: Campona Airmaster™ 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.
Campona Airmaster™ 50 microgram/500 microgram/ dose inhalation powder, pre-dispensed.123
Chronic Obstructive Pulmonary Disease (COPD)
Campona Airmaster™ is indicated for the symptomatic treatment of patients with COPD, with a FEV1 < 60 % predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
*Only the 50/500mcg Campona strength is indicated for the treatment of COPD.3
50/100mcg
50/250mcg
50/500mcg*
Why Campona Airmaster™?
Explore More
References
By clicking the below links you will be leaving a Genesis Pharmaceutical website and entering a website that is not controlled by Genesis Pharmaceuticals.
1. Campona airmaster™ 50 micrograms / 100 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).
2. Campona airmaster™ 50 micrograms / 250 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).
3. Campona airmaster™ 50 micrograms / 500 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).
4. Medicinal forms fluticasone with salmeterol. NICE. Available here. (Accessed: 20 September 2023).
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Activase Pharmaceuticals at eupvg@genreg.eu or 02072010421